⚕ GalenOps field
←

SITE008-0067

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2022-05-14

AEs
10
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-06-06 (study day 11); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-06-17 (study day 22); relationship: not assessed

severe assessed

Grade 3 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-06-30 (study day 35); relationship: not assessed

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-07-08 (study day 43); relationship: N

severe serious assessed

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-08-09 (study day 75); relationship: not assessed; serious criteria: life-threatening

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-04 (study day 101); relationship: N

moderate assessed

Grade 2 Hepatitis — outcome: RECOVERED/RESOLVED; onset 2022-09-15 (study day 112); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-09-30 (study day 127); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-04 (study day 131); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-27 (study day 185); relationship: not assessed

Data queries

No data queries.